Product Description
intravenous immunoglobulin) for the anti-donor antibody positive recipient in need of pre-transplant desensitization for End Stage Renal Disease (Sourced from: https://clinicaltrials.gov/ct2/show/NCT02032095)
Mechanisms of Action: Unknown
Novel Mechanism: No
Modality: Antibody
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Japan Blood Products Organization
Company Location: Asia Pacific
Company Founding Year: 2012
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Muscle Weakness|Polymyositis|Dermatomyositis|Guillain-Barre Syndrome|Myasthenia Gravis|Kidney Failure, Chronic|Abortion, Spontaneous|Abortion, Habitual
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT02184741 |
B211-11 | P3 |
Completed |
Abortion, Habitual|Abortion, Spontaneous |
2020-05-01 |
36% |
2022-01-29 |
Primary Endpoints|Start Date|Treatments |
NCT02342184 |
B211-13 | P3 |
Completed |
Guillain-Barre Syndrome |
2015-09-01 |
2019-03-20 |
Treatments |
|
NCT02032095 |
B211-10 | P3 |
Completed |
Kidney Failure, Chronic |
2015-09-01 |
2019-03-20 |
Treatments |
|
NCT00515450 |
0998-B1 | P3 |
Completed |
Myasthenia Gravis|Muscle Weakness |
2010-05-01 |
2019-03-21 |
Treatments |
|
NCT00335985 |
PM/DM | P3 |
Completed |
Dermatomyositis|Polymyositis |
2009-03-01 |
2019-03-21 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|